(Q38170812)

30 August 2017

Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder (English)

1 reference

30 August 2017

0 references

3

Yair Lotan

1 reference

30 August 2017

6

Pierre I Karakiewicz

1 reference

30 August 2017

7

Shahrokh F Shariat

1 reference

30 August 2017

2

Luis A Kluth

1 reference

30 August 2017

1

Evanguelos Xylinas

1 reference

30 August 2017

5

Malte Rieken

1 reference

30 August 2017

4

Siamak Daneshmand

1 reference

30 August 2017

12 December 2013

1 reference

30 August 2017

1 reference

30 August 2017

32

1 reference

30 August 2017

3

1 reference

30 August 2017

230-242

1 reference

Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Nomograms provide improved accuracy for predicting survival after radical cystectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Immunohistochemical biomarkers for bladder cancer prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Epigenetic markers as promising prognosticators for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Molecular markers in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Bladder cancer: nomogram aids clinical decision making after radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Molecular markers for detection, surveillance and prognostication of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

7 January 2021

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Accumulation of nuclear p53 and tumor progression in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

p53 expression in patients with advanced urothelial cancer of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

p53 immunohistochemistry in bladder cancer--a new approach to an old question

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Prognostic value of p53 for high risk superficial bladder cancer with long-term followup.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

A six-week course of bacillus Calmette-Guérin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

An overview of the cell cycle arrest protein, p21(WAF1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Survivin: a promising biomarker for detection and prognosis of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Effects of physiologic pacing versus ventricular pacing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Survivin, versatile modulation of cell division and apoptosis in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Urine detection of survivin and diagnosis of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Survivin expression is associated with bladder cancer presence, stage, progression, and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

A survivin gene signature predicts aggressive tumor behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Targeting angiogenesis in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Molecular pathogenesis and diagnostics of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

erbB receptor expression patterns in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Targeting the PI3K signaling pathway in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Impact of gender on bladder cancer incidence, staging, and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Detection of circulating tumor cells in patients with urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

TGFB1andTGFBR1polymorphic variants in relationship to bladder cancer risk and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Matrix metalloproteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.009

10.1016/J.UROLONC.2013.06.009

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24332648